P&G's Aleve first in adverse drug experience reports to FDA in 1995.
This article was originally published in The Tan Sheet
Executive Summary
ALEVE FIRST IN FDA POST-MARKETING ADE REPORTS, according to the agency's 1995 Annual Adverse Drug Experience Report released in late January by FDA's Division of Pharmacovigilance & Epidemiology. The nonprescription nonsteroidal anti-inflammatory drug naproxen sodium ranked first among the top ADEs for both prescription and OTC drugs with 5% (6,642) of the total reports. Procter & Gamble marketed Aleve in 1995. The brand is now sold by Bayer under a September 1996 agreement with Roche ("The Tan Sheet" Sept. 23, 1996, p. 10).